<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106468</url>
  </required_header>
  <id_info>
    <org_study_id>Elgendy - 1</org_study_id>
    <nct_id>NCT02106468</nct_id>
  </id_info>
  <brief_title>The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus</brief_title>
  <official_title>The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus and Improvement of Quality of Life: A Randomized, Double Blind, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>October 6 University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>October 6 University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was initiated to evaluate the potential of dietary supplementation of omega-3 for
      providing an inexpensive, safe and effective therapeutic agent for managing atrophic/erosive
      lichen planus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improve quality of the life (Oral Health Impact Profile)</measure>
    <time_frame>6 months</time_frame>
    <description>Improve quality of the life was recorded at baseline, 3 and 6 months after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size and types (atrophic/erosive) of the lesions</measure>
    <time_frame>6 months</time_frame>
    <description>Size and types of the lesions were examined at the beginning of treatment, and then after 2 weeks, 1, 3, and 6 months of therapy.
Score 5 = white striae with erosive area more than I cm Score 4 = white striae with erosive area less than 1 cm Score 3 = white striae with atrophic area more than I cm Score 2 = white striae with atrophic area less than I cm Score I =mild white striae, no erythematous area Score 0 = no lesion, normal mucosa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score (Visual analogue scale (VAS)),</measure>
    <time_frame>6 months</time_frame>
    <description>Pain score was recorded at the beginning of treatment, and then after 2 weeks, 1, 3, and 6 months of therapy.
Scale 0: no pain: VAS=0 Scale 1: mild pain: 0&lt; VAS≤3.5 Scale 2: moderate pain: 3.5 &lt;VAS≤7 Scale 3: severe pain: 7&lt; VAS≤10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of disease</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrence within the following 3 months was recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>prednisone 50 mg tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 capsules 1000 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone tablet 5mg</intervention_name>
    <description>This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.</description>
    <arm_group_label>prednisone 50 mg tablet</arm_group_label>
    <other_name>Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 soft capsules 1000 mg</intervention_name>
    <description>This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.</description>
    <arm_group_label>Omega-3 capsules 1000 mg</arm_group_label>
    <other_name>Super Omega; Technopharma, Cairo, Egypt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of OLP (Presence of painful and atrophic-erosive oral Lesions,
             bilateral, mostly symmetrical lesions, presence of lace-like network of slightly
             raised white lines).

          2. Age between 30-60 years

          3. Ability to complete the present clinical trial.

        Exclusion Criteria:

          1. Pregnant or breast feeding women (pregnancy test for women of child bearing age).

          2. Lichenoid reactions caused by certain drugs or dental amalgam.

          3. Therapy for oral lichen planus (OLP) in the 6 months prior to the study.

          4. Patient doesn't have hepatitis C [after the patients' medical histories were recorded,
             the patients were given hepatic screening as published elsewhere. 2

          5. Presence of candidiasis before treatment.

          6. Patients with pre-existing diabetes or an initial random glucose level exceeding 200
             mg/dL before initiating steroid therapy were excluded.

          7. Hypertensive patients

          8. Contraindications for corticosteroid use (immunodeficiency or severe heamatological
             alterations).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enas Elgendy, ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>October 6 University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>October 6 University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>April 26, 2015</last_update_submitted>
  <last_update_submitted_qc>April 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>October 6 University</investigator_affiliation>
    <investigator_full_name>Enas Elgendy</investigator_full_name>
    <investigator_title>Lecuture, October 6 University</investigator_title>
  </responsible_party>
  <keyword>Oral Lichen Planus</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Omega -3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus</mesh_term>
    <mesh_term>Lichen Planus, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

